Purpose: Laparoscopy-assisted distal gastrectomy for early gastric cancer has gained acceptance and popularity worldwide. However, laparoscopy-assisted distal gastrectomy for advanced gastric cancer is still controversial. Therefore, we propose this prospective randomized controlled multi-center trial in order to evaluate the safety and feasibility of laparoscopy assisted D2-gastrectomy for advanced stage gastric cancer. Materials and Methods: Patients undergoing distal gastrectomy for advanced gastric cancer staged cT2/3/4 cN0/1/2/3a cM0 by endoscopy and computed tomography are eligible for enrollment after giving their informed consent. Patients will be randomized either to laparoscopyassisted distal gastrectomy or open distal gastrectomy. Sample size calculation revealed that 102 patients are to be included per treatment arm. The primary endpoint is the non-compliance rate of D2 dissection; relevant secondary endpoints are three-year disease free survival, surgical and postoperative complications, hospital stay and unanimity rate of D2 dissection evaluated by reviewing the intraoperative video documentation. Discussion: Oncologic safety is the major concern regarding laparoscopy-assisted distal gastrectomy for advanced gastric cancer. Therefore, the non-compliance rate of clearing the N2 area was chosen as the most important parameter for the technical feasibility of the laparoscopic procedure. Furthermore, surgical quality will be carefully reviewed, that is, three independent experts will review the video records and score with a check list. For a long-term result, disease free survival is considered a secondary endpoint for this trial. This study will offer promising evidence of the feasibility and safety of Laparoscopy-assisted distal gastrectomy for advanced gastric cancer. Trial Registration: NCT01088204 (international), 
Introduction
Minimally invasive surgery has become a treatment option for cancer. In Korea, laparoscopy-assisted distal gastrectomy (LADG) for early gastric cancer has gained acceptance and became a treat- 
Randomization and surgical procedures
After consenting in participation of the trial, patients are preoperatively randomized to either of the two treatment groups (LADG or open distal gastrectomy, the procedures are displayed in detail in ment option. 1, 2 Many randomized controlled studies reported that LADG had better short-term results such as a less pain, earlier mobilization, faster recovery of bowel function, shorter hospital stay, better cosmetic effect, and improved quality of life (QoL). [3] [4] [5] [6] [7] [8] Moreover, some retrospective studies showed comparable long-term survival. [9] [10] [11] According to the study by An et al., 11 
Study objectives 1) Primary endpoint
Primary efficacy endpoint is the evaluation of feasibility of D2 lymph node dissection by laparoscopic surgery compared to open distal gastrectomy by calculating the non-compliance rate between the two groups. The non-compliance rate is defined as the proportion of patients with more than one missing lymph node station.
The compliance rate was first reported in the Dutch D2 trial. 21 Non-compliance is being determined in the pathologic report.
After oncologic dissection the surgeons dissect each lymph node station from the removed specimens and send them separately for pathologic examination. If the pathologist does not find any lymph nodes in more than one lymph node station, the definition of noncompliance is met.
2) Secondary endpoints
Major secondary endpoints are surgical and oncologic outcomes.
The following surgical outcomes are evaluated: Hospital stay, operating time, time to first flatus, surgical stress by measurement of serum C-reactive protein (CRP), and interleukin-6 (IL-6) levels.
Postoperative complications are recorded according to the Accordion Severity System. 22 Medical complications (pulmonary, vascu- 
Methods against bias 1) Selection bias
Randomization into two treatment groups will be performed in order to omit selection bias from this trial. Comparable intervention groups are achieved by block randomization using a web based randomization tool (eVelos [http://eresearch.ncc.re.kr/eres/jsp/ ereslogin.jsp]). Randomization is stratified according to center and clinical stage in fixed block sizes (1 : 1 allocation ratio) in order to achieve equal groups.
2) Information bias
Blinding procedures are not possible in this trial due to the nature of the intervention. Patient and observers for postoperative outcomes are blinded to guarantee an optimal study outcome.
3) Confounding
Potential confounding will be reduced by the randomization process. In order to reduce procedural outcomes all surgical proce-dures are going to be defined in operating manuals. Further intraoperative photo documentation is mandatory to proof completeness of D2 dissection in open resections. Unedited video documentation is mandatory for the laparoscopic cases. Surgical quality will be reviewed by three independent and randomly assigned experts using an evaluation tool (Appendix 2). Postoperative care is standardized.
Blinded assessment of the primary outcome will be provided by blinded observers. Patient blinding will not be possible due to the nature of the surgical procedure.
Sample size calculation
The present study aims to evaluate the surgical and oncological safety of LADG with D2 lymph node dissection, and the primary end point is non-compliance rate. The trial hypothesis is the noncompliance rate for LADG does not statistically differ from the one for open distal gastrectomy. We, first, evaluated the compliance rate for open approach in the institutional database of more than 5,000
cases and found it to be about 60%. 23 Therefore, we expected 60% of the compliance rate for LADG and the expected compliance rate will be estimated with the following precision: margin of error of 10% with 95% confidence level. The sample size needed based on the above mentioned considerations would be 92 patients per treatment group. Considering a 10% of follow-up loss, 102 patients per each arm have to be enrolled. Thus a total of 204 patients are to be enrolled in this study.
Documentation and data handling
All protocol required information collected during this trial is entered in the electronic case report form (eCRF) using the web based eVelos system (http://eresearch.ncc.re.kr/eres/jsp/ereslogin. jsp). The completed eCRFs are reviewed and signed by the investigator or subinvestigator and sent to the independent data management group in the eVelos team. Quality control is being enforced by site visits and CRF review. The data is going to be handled, managed and analyzed according to appropriate regional standard operating procedures.
Discussion
This will be the first randomized controlled study to evaluate the feasibility of LADG in patients with AGC. We Oncologic safety is supposed to be the major concern among many surgeons. In order to achieve the best possible oncologic result, D2 dissection is considered standard of care, especially in advanced stage gastric cancer. 24 The importance of D2 dissection for locally AGC has been demonstrated in several multicenter trials. [24] [25] [26] There is evidence that adequate D2 lymphadenectomy seems to be sufficient to control tumor recurrence. The trial by Sasako et al. 25 showed that five year survival rates for patients undergoing surgery only were between 70% and 80%. Another trial by Sakuramoto et al. 26 confirmed an overall five year survival rate of approximately 65%. Even European trials reported improved long-term outcomes for patients having undergone D2 dissection when postoperative morbidity and mortality can be kept at an acceptable level. The primary endpoint of non-compliance rate of clearing the N2 area was chosen as the most important parameter for the technical feasibility of the laparoscopic procedure. Non-compliance in D2 dissection is defined as inability to retrieve lymph nodes from more than one lymph node station as they are defined by JRSGC guidelines. 20 In this trial, the lymph node stations are separated by the responsible surgeon and sent for pathologic examination. If the pathologist is unable to find any lymph nodes in more than one of the respective stations, non-compliance is confirmed. The compliance rate of D2 dissection is a widely accepted endpoint measure and was already applied in a prospective clinical trials. 21 22 The Accordion Severity Classification System can be easily used for small and large studies and is independent on the surgical procedure investigated. We chose the Expanded Version for complication classification as we consider D2 gastrectomy a complex procedure bearing potential risks for the patients, especially in advanced stage gastric cancer. The profile of intra-and postoperative complications for possible complications in laparoscopic gastric cancer surgery was published by our institution before. 27 It might be debatable why QoL will not be evaluated in this trial as a secondary endpoint. The principal investigator already conducted a trial with a focus on QoL evaluation and found out that short term improvements in postoperative QoL were observed in the laparoscopic group. 6 Therefore evaluation of QoL was not reconsidered in this trial, although it is conceivable that perception of QoL might be different (better) in advanced stage gastric cancer patients.
Further surgical quality will be carefully reviewed in this trial.
Three independent experts are reviewing the video records of all laparoscopic procedures. Oncologic safety is of utmost importance in this trial, especially for advanced stage gastric cancer patients.
Video and photo documentation are considered to ensure homogenous surgical quality over all participating centers, although surgical expertise for laparoscopic gastric cancer surgery is excellent among the (sub-)investigators. All participating surgeons are obliged to having performed over 50 cases of laparoscopy assisted distal gastrectomies before the study. As open D2 gastrectomy is a standard procedure in Korea, no specific training for the lymph node dissection itself is considered necessary.
Conclusively this randomized controlled trial is believed to confirm feasibility and safety of laparoscopy assisted distal gastrectomy with D2 lymph node dissection for advanced stage gastric cancer patients.
